Industry comments on ANZTPA’s joint framework
AusBiotech has made a submission on behalf of the biotechnology industry to the Australia New Zealand Therapeutic Products Agency’s (ANZTPA) discussion paper.
AusBiotech has made a submission on behalf of the biotechnology industry to the Australia New Zealand Therapeutic Products Agency’s (ANZTPA) discussion paper: ANZTPA implementation - Release of high level description of a possible joint regulatory scheme.
Through the consultation process, the Therapeutic Goods Administration (TGA) and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) requested comment to help inform the development of the regulatory framework for ANZTPA, a joint trans-Tasman agency with responsibility for regulating therapeutic products across both countries.
AusBiotech commented on:
- 3rd Party Conformity Assessment
- Change in regulatory burden in New Zealand
- Transition periods
- Resource implications
- Clinical trials (CTN/CTX scheme)
- Product approvals
- In vitro diagnostics (risk classification and access for home-use)
- Clarification on exemption for blood and blood components
- Clarification on the use of biologicals within IVDs
The full AusBiotech submission can be found here.
The discussion paper can be found here.
Enquires regarding the AusBiotech submission may be directed to Alina Tooley, National Manager Programs or on +61 3 9828 1425.
Brain cells mature faster in space than on Earth
Microgravity is known to alter the muscles, bones, the immune system and cognition, but little is...
Fetuses can fight infections within the womb
A fetus has a functional immune system that is well-equipped to combat infections in its...
Gene therapy reverses heart failure in large animal model
The therapy increases the amount of blood the heart can pump and dramatically improves survival,...
